Hence, according to available data, patients with early-onset AD and MCI with clear β-amyloid plaques who are willing and able to undergo periodic follow-up with imaging studies such as PET and safety MRI and APOE4 genotype testing are good candidates for this drug. Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug. Knopman et al. published a critical review of the two aducanumab trials.16 The authors state that although it is possible that aducanumab has cognitive benefits, the available data are insufficient to make a “claim of efficacy” for the drug.
During the clinical trials of the drug, 40 per cent of the phase-3 trial participants, who received a higher dosage of Aducanumab, experienced brain swelling or bleeding. According to reports, most were either asymptomatic or had headaches, dizziness or nausea. While Aducanumab has been approved by FDA, there has been a major controversy over the clinical trials conducted to test the drug. While the first showed some improvement in patients, the second failed to show any benefit.
Its makers propose it does this by clearing amyloid beta that builds up in the brain. However, these effects have only been shown in people living with mild memory or thinking problems. The annual cost of $50,000 for aducanumab that has been suggested by market analysts would not be commensurate with its clinical benefits. Several anti-amyloid beta and anti-tau therapies have been evaluated or are currently under evaluation. Anti-β-amyloid therapies act by reducing the pathologic β-amyloid oligomers or by inhibiting β-amyloid plaque formation or by increasing clearance of β-amyloid peptides. However, many of the trials on anti-β-amyloid therapies have failed to demonstrate clinical impact or pose safety concerns.
- Ten out of 11 members of the federal panel of medical experts voted that it was “not reasonable to consider the research presented as “primary evidence of the effectiveness of Aducanumab for the treatment of Alzheimer’s disease,” the New York Times reported.
- The company has said the average wholesale cost would be $56,000 (over Rs 40 lakh) per year.
- As such, the data were reviewed by the agency’s Peripheral and Central Nervous System Drugs Advisory Committee in November 2020, who ultimately voted to not recommend regulatory approval.
What has been shown is that it reduces plaque formation,” Dr Deshpande said. Aducanumab, from the company Biogen, has been approved by the US Food and Drug Administration https://1investing.in/ (FDA) — the first new medication for Alzheimer’s to get FDA approval in nearly two decades. The dosing should be titrated, reaching 10 mg/kg by the seventh infusion.
It also reported micro-haemorrhages in 31.4% participants as compared with 13.6% in the placebo group. We help you access elsewhere approved medicines, no matter where you live. To date, we have assisted patients in over 88 countries to access thousands of life-improving medicines. The shipping prices are dependent on the type of shipping necessary for the particular medicine (regular or cold chain) and upon the destination country. The shipping fees may include the shipping from our supplier to our partner pharmacy as well as the shipping costs to deliver the medicine to the patient’s country of residence. The shipping fee might also include the cost of special packaging, such as coolboxes, cool packs and data loggers, as well as transport insurance to guarantee that you receive your medicine in good order.
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Stop the infusion upon the first observation of any signs or symptoms consistent with allergic reaction. The Alzheimer Society of Canada trusts and supports Health Canada’s regulatory expertise and decision-making in this matter. On December 20, 2021, the drug’s maker, Biogen, announced it would be reducing the cost of the drug. According to World Health Organization aducanumab price in india (WHO) estimates for 2017, dementia affects approximately 50 million people worldwide, a number that is projected to grow to 82 million by 2030. In India, it is estimated that 5.3 million people (1 in 27) above the age of 60 have dementia in 2020, according to the Dementia in India 2020 report published by the Alzheimer’s and Related Disorders Society of India.
Unfortunately, the Early Access Program of the manufacturer does NOT enroll patients in .
“The side-effects were more with Aducanumab and there weren’t any functional benefits. Lecanemab has fewer side-effects and has shown functional improvement to offset the risks. The results announced for the new drug show it has a similar safety profile,” said Dr MV Padma Srivastava, head of the neurosciences centre at the All India Institute of Medical Sciences (AIIMS). Our Access Support Team will be able to give you information about the Early Access Program of the manufacturer. If the patient meets the conditions set by the manufacturer and qualifies, they might be able to get access to Aduhelm (aducanumab-avwa) at no cost or for a reduced price. Your information will only be used to process your enquiry and will not be shared with third parties.
In January 2024, drug-maker Biogen announced it would be discontinuing the development and commercialization of aducanumab/Aduhelm worldwide, as well as ending a related clinical study. Aducanumab (brand name Aduhelm) was an Alzheimer’s disease drug that received much global news coverage in 2021 and 2022. The drug was not commercially available in Canada, as drug-maker Biogen withdrew it from Health Canada review in June 2022.
Always consult your treating physician before starting a course of treatment. Generally, our Named Patient support fee, shipping costs and any local tax (if applicable) are not included in the product price that is displayed on our website unless stated otherwise. Biogen, which developed Aduhelm with Japan’s Eisai Co., said last week the company expects to screen the first patients for their next study in May. Researchers will aim to enroll about 1,300 people with early-stage Alzheimer’s and expects to complete the research about four years after the study begins. Doctors have said concerns over the price were compounded by costs patients also would face for regular testing and scans needed to monitor their progress on Aduhelm. But Aduhelm’s debut has been slowed by concerns over the price and research behind the drug.
How does the new drug work?
Relevant search terms such as aducanumab OR anti beta-amyloid therapy OR immunotherapy OR monoclonal antibody and Alzheimer’s disease OR dementia OR mild cognitive impairment were used. Google Scholar, Web of Science, and MEDLINE databases and manufacturer’s website were searched to identify clinical trials, reviews, and updates on aducanumab in patients with AD. Aducanumab is a medication used in the management and treatment of Alzheimer disease. This activity describes the indications, action, and contraindications for aducanumab as a possible agent in the management of Alzheimer disease. Aducanumab indications in Alzheimer disease are specific to subjects with mild cognitive impairment or mild dementia stage of the progressive neurodegenerative ailment. The approval of the first disease-targeting antiamyloid β-drug is likely to inflate the hopes of patients with Alzheimer’s disease.
Looking for more information? Download your free guide on: “How to import a medicine”.
The development and commercialization of this drug was never approved nor commercially distributed in Canada, and its maker has announced a plan to discontinue distribution in the U.S. in 2024. “It is a novel drug that is designed to slow the progression of Alzheimer’s and not a cure. Still, trial results are not convincing,” said Dr Manoj Hunnur, Mumbai-based neurologist.
Medications approved for Alzheimer’s disease in Canada
Additionally, we foresee issues of equity in access to treatment of AD based on lack of knowledge, stigma and cost of treatment, especially amongst minorities and ethnic communities. Pregnant patients considering aducanumab should be advised that there are no data from reproductive studies in humans. Adacunumab in animal reproductive studies demonstrated no adverse effects, but the findings may have no relevance in humans. The interprofessional healthcare team should thoroughly educate and discuss aducanumab, its adverse effects, and therapy aims with patients and their caretakers. Perpetual intercommunication within the healthcare team in managing AD patients receiving aducanumab can potentially improve patient outcomes. The neurologist should fully advise patients of the potential adverse effects of ARIA and its asymptomatic or clinical manifestations.
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team. For EMA approved medicines with prescriptions from within the Schengen zone, you can pick the medicines up from our partner pharmacy in Amsterdam, Luxembourg or Dusseldorf. For non-EMA approved medicines, with prescriptions from within the Schengen zone, you can pick the medicines up in our partner pharmacy in Dusseldorf. If you have requested to collect your medicines, you will receive a notification when the medicines are in the pharmacy and ready for you. We help you access approved medicines that are not approved or available in your country of residence.